Pharma Partners Gilead and LEO Pharma Forge Strategic Partnership to Advance Oral STAT6 Program for Inflammatory Diseases Pharma Partners Gilead Sciences and LEO Pharma today announced a groundbreaking strategic partnership designed to accelerate the development and commercialization of LEO Pharma’s…
Alnylam Pharmaceuticals Reports Preliminary 2024 Financials, 2025 Revenue and Pipeline Guidance Alnylam Pharmaceuticals Reports a global leader in RNA interference (RNAi) therapeutics, today released preliminary financial results for the fourth quarter and full year 2024, alongside its guidance for 2025…
Ascendis Pharma A/S has provided a comprehensive update on its business and strategic roadmap for 2025, highlighting key milestones and growth opportunities. This update was presented by Jan Mikkelsen, President and CEO, at the 43rd Annual J.P. Morgan Healthcare Conference.…
Roche Acquires Poseida Therapeutics: $9.00 per Share Tender Offer Completed Poseida Therapeutics Roche a global leader in the pharmaceutical and diagnostics industries, has announced the successful completion of its tender offer to acquire Poseida Therapeutics. This move marks a significant…
A Cautiously Optimistic Outlook for Biopharma in 2025 The biopharma sector is poised for a cautious but optimistic rebound in 2025, driven by renewed investment, the growing influence of artificial intelligence (AI), and a continued focus on late-stage assets and…
CVS Health and Aetna Allocate $750,000 in Grants to Advance Health Outcomes Across Illinois CVS Health and Aetna Better Health® of Illinois, a CVS Health company, recently announced a combined $750,000 in community grants to organizations dedicated to enhancing health…
Trispecific WuXi Biologics a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a groundbreaking partnership with Candid Therapeutics, Inc. (“Candid”). Candid is a clinical-stage biotechnology firm aiming to lead advancements in T-cell engager therapies for autoimmune and…
Astellas Pharma recently announced the approval Gastric Cancer of VYLOYTM (zolbetuximab) by China’s National Medical Products Administration (NMPA) for first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.…
Revolution Medicines, a clinical-stage oncology company focused on developing targeted therapies for patients with RAS-addicted cancers, recently announced the successful closing of its upsized underwritten public offering. The offering comprised 16,576,088 shares of common stock, priced at $46.00 per share,…
WuXi AppTec Recognized for Its Continued Commitment to Environmental, Social, and Governance Excellence WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has proudly announced its inclusion in the 2024 Dow Jones Sustainability Indices (DJSI) for the…
OS Therapies Announces $6 Million Private Placement to Fund Clinical Development of OST-HER2 for Osteosarcoma and Other Cancer Indications OS Therapies, a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies and antibody-drug conjugates, has successfully closed a private placement…
The Future of Cancer Immunotherapy: Market Insights 2025-2029 The report titled “Cancer Immunotherapy Market 2025-2029 – Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant Guides” has been added to ResearchAndMarkets.com’s offerings. It aims to shed…